These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3868024)

  • 1. The clinical pharmacology of acyclovir and its prodrugs.
    Brigden D; Whiteman P
    Scand J Infect Dis Suppl; 1985; 47():33-9. PubMed ID: 3868024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir.
    Selby P; Powles RL; Blake S; Stolle K; Mbidde EK; McElwain TJ; Hickmott E; Whiteman PD
    Lancet; 1984 Dec; 2(8417-8418):1428-30. PubMed ID: 6151046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
    de Miranda P; Burnette TC
    Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.
    Krenitsky TA; Hall WW; de Miranda P; Beauchamp LM; Schaeffer HJ; Whiteman PD
    Proc Natl Acad Sci U S A; 1984 May; 81(10):3209-13. PubMed ID: 6587347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.
    Good SS; Krasny HC; Elion GB; de Miranda P
    J Pharmacol Exp Ther; 1983 Dec; 227(3):644-51. PubMed ID: 6655561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A515U: a prodrug of acyclovir with increased oral bioavailability.
    Rees PJ; Selby P; Prentice HG; Whiteman PD; Grant DM
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():215-22. PubMed ID: 3793661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers.
    Whiteman PD; Bye A; Fowle AS; Jeal S; Land G; Posner J
    Eur J Clin Pharmacol; 1984; 27(4):471-5. PubMed ID: 6549167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir--and beyond.
    Darby G
    J Int Med Res; 1994; 22 Suppl 1():33A-42A. PubMed ID: 8063023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
    Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
    J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
    Burnette TC; de Miranda P
    Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
    Anand BS; Katragadda S; Mitra AK
    J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
    Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
    Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design.
    Santos CR; Capela R; Pereira CS; Valente E; Gouveia L; Pannecouque C; De Clercq E; Moreira R; Gomes P
    Eur J Med Chem; 2009 Jun; 44(6):2339-46. PubMed ID: 18848738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action, pharmacokinetics and toxicity of acyclovir--a review.
    Brigden D; Whiteman P
    J Infect; 1983 May; 6(1 Suppl):3-9. PubMed ID: 6350472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir concentrations in human breast milk after valaciclovir administration.
    Sheffield JS; Fish DN; Hollier LM; Cadematori S; Nobles BJ; Wendel GD
    Am J Obstet Gynecol; 2002 Jan; 186(1):100-2. PubMed ID: 11810093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.
    Tod M; Lokiec F; Bidault R; De Bony F; Petitjean O; Aujard Y
    Antimicrob Agents Chemother; 2001 Jan; 45(1):150-7. PubMed ID: 11120958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on acyclovir: oral therapy for herpesvirus infections.
    True BL; Carter BL
    Clin Pharm; 1984; 3(6):607-13. PubMed ID: 6096075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
    Tyring SK; Baker D; Snowden W
    J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe central nervous system symptoms following oral administration of acyclovir in a patient with chronic renal failure: a case report].
    Niibori D; Fujisawa M; Matsuzaki M
    Hinyokika Kiyo; 1993 May; 39(5):459-61. PubMed ID: 8322628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.